|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:founded
|
1964
|
|
gptkbp:founder
|
gptkb:Busaburo_Otsuka
|
|
gptkbp:headquarters_location
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Otsuka Pharmaceutical
|
|
gptkbp:industry
|
pharmaceuticals
nutraceuticals
|
|
gptkbp:keyPerson
|
gptkb:Tatsuo_Higuchi
gptkb:Makoto_Inoue
|
|
gptkbp:logo
|
Otsuka Pharmaceutical logo.svg
|
|
gptkbp:member
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:notableProduct
|
gptkb:Rexulti
gptkb:Samsca
gptkb:Abilify
gptkb:Oronamin_C
gptkb:Pocari_Sweat
|
|
gptkbp:numberOfEmployees
|
about 30,000
|
|
gptkbp:parentCompany
|
gptkb:Otsuka_Holdings
|
|
gptkbp:researchInterest
|
oncology
cardiovascular diseases
central nervous system disorders
nutritional products
|
|
gptkbp:revenue
|
over $10 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Otsuka_Pharmaceutical_Europe_Ltd.
gptkb:Taiho_Pharmaceutical
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
|
gptkbp:website
|
https://www.otsuka.co.jp/en/
|
|
gptkbp:bfsParent
|
gptkb:Pocari_Sweat
gptkb:Tokushima_Vortis
gptkb:PhoreMost
gptkb:Japanese_postwar_economic_miracle
gptkb:Astex_Therapeutics
gptkb:aripiprazole
gptkb:PhRMA
|
|
gptkbp:bfsLayer
|
6
|